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Abstract 
Protein design methods have been applied to engineer novel protein folds, enzymes, and 
materials with atomic-level accuracy. However, little work has been done to apply it to engineer 
novel proteins that can be used in vivo to dissect biological processes. Here we utilize protein 
design to study the cellular signaling involved in cell motility. Cell motility is driven by the 
reorganization of the cytoskeleton, a process regulated by the Rho protein family of small 
GTPases. These molecules are activated at precise subcellular locations by guanine exchange 
factors (GEFs) with fine temporal control. Understanding the biological role of these molecules 
requires their investigation at the subcellular level in living cells. To this end, we developed 
photoactivatable GEF inhibitors to allow for the spatio-temporal control of these GTPases. The 
GEFs targeted in this work were GEF-H1 and the members of Vav family GEFs, specifically Vav2. 
The two serve orthogonal roles in cell motility, where GEF-H1 has GEF activity towards RhoA at 
the retracting edge, Vav targets Rac1 at the leading edge. Our computational work generated a 
library of GEF-H1 inhibitors, and two experimentally validated inhibitors for the Vav family 
displaying high specificity in silico.   
 
Introduction 
Cell movement is critical in development, immune surveillance, and wound healing. It 
usually becomes disrupted in cancer.1) Cell motility is driven by the reorganization of the 
cytoskeleton, a process regulated by the Rho protein family of small GTPases. There are 22 known 
human members of the Rho family. These molecules are activated at precise subcellular locations 
by switching between an inactive GDP bound state and an active GTP bound state. This control is 
conferred primarily by two regulatory families of proteins. GTPase-activating proteins (GAPs) 
increase the intrinsic GTPase activity of Rho GTPases therefore inactivating them. Guanine 
nucleotide exchange factors (GEFs) catalyze the exchange of GDP for GTP. GEFs and GAPs are 
extensively regulated subsequently dictating the activation and inactivation dynamics of GTPases 
with fine spatiotemporal control.2)  
The Dbl family of RhoGEF targets Rho GTPases specifically. Each member contains a Dbl 
homology (DH) domain and an adjacent, C-terminal, pleckstrin homology (PH) domain. The DH 
domain is responsible for the activation of GTPases, while the PH domain is thought to localize 
DbI proteins to plasma membranes and to regulate GEF activity via allosteric interactions.2)  
The GEFs of interest in this study are GEF-H1 and the Vav family of proteins. GEF-H1 is 
an activator of the Rho GTPase RhoA. RhoA plays a critical role at the advancing and retracting 
edges of moving cells.3) Active RhoA stimulates many downstream effectors, such as mDia1 that 
leads to actin polymerization and myosin II that leads to cell contraction.4) GEF-H1 knockdown 
results in decreased RhoA activation at the leading edge, impaired membrane protrusion, and 
significantly reduced motility in many different cell lines.5) GEF-H1 is the only known GEF that 
localizes at the microtubules in its inactive state and microtubule release leads to its activation.1) 
Therefore, GEF-H1 couples microtubule dynamics with Rho GTPase activation and changes in 
the actin cytoskeleton.5) 
The Vav family of proteins contains 3 isoforms: Vav1, Vav2, and Vav3. Vav1 is primarily 
expressed in hematopoietic cells, whereas Vav2 and Vav3 are more ubiquitously expressed. Vav 
proteins are thought to primarily target the GTPase Rac1. Rac1 is the primary regulator of actin 
cytoskeleton reorganization, where it mediates lamellipodia formation and membrane ruffles in 
response to extracellular signaling.6) Through knockdown studies it is known that Vav proteins are 
critical to T and B cell receptor responses propagating cytoskeletal rearrangement for processes 
including the formation of the immunological synapse, phagocytosis, and integrin mediated T-cell 
spreading.7) 
Results 
 
 
 
Computational generation of Vav inhibitor library:  
To computationally model Vav2 we utilized the Vav1 crystal structure because of the high 
sequence homology between the two and the lack of a Vav2 crystal structure. Vav is autoinhibited 
by a helix, termed the AID , from its AC domain that binds to its catalytic DH domain. The 
computational approach used for inhibitor design used the Rosetta macromolecular modeling 
software8) to engineer scaffold proteins maintaining and adding to the  contacts of the AID on the 
DH domain of Vav. Proteins containing helices that align well with the inhibitory helix were 
utilized. Zdark a 3 helical protein part of the LOV2/Zdark9) light inducible and reversible dimer 
was used as the scaffold to be engineered for Vav binding. Our modeling shows that LOV/Zdark 
complex formation will satirically block the interaction between Zdark and Vav, because of 
clashes between LOV and Vav. Light irradiation would cause the complex to dissociate, allowing 
the engineered inhibitors to bind to Vav and block its GTPase interaction, therefore conferring 
photo inhibition towards Vav. This LOV2/Zdark system has proven competent in controlling the 
localization and activity of proteins caged to them.9) 
The residue critical for interaction is the central Tyr174 within the AC domain that makes 
contact with Arg332 within the DH domain to form a salt bridge.  Tyr174 in addition toMet176 
were grafted onto Zdark within a LOV2 non-interacting helix at position 49. Residues not 
interacting with LOV2 making contact with the active site were allowed to mutate during the 
computational modeling. Local docking and fine backbone movements10) of the Zdark around the 
active site was then undergone. To evaluate the ability of designs to fold and bind, we 
computationally filtered by Rosetta metrics such as the solvent exposed surface area (SASA), the 
binding energy (ddG), and the shape complementary (Sc) of the interface. The top 2,000 designs 
passing filtering were used to construct a ~two million amino acid diverse library with the 
SwiftLib8 software along with manual optimization.  
Computational generation of GEF-H1 inhibitor library:  
There is no crystal structure for GEF-H1, however the DH domain in DbI GEFs is highly 
conserved. We therefore computationally predicted the structure of the GEF-H1 DH domain by 
grafting the DH domain residues of GEF-H1 onto the backbone of the Vav1 crystal structure. 
Several rounds of side chain minimization and backbone perturbation were done to determine the 
GEF-H1 structure used for modeling. GEF-H1 sequence alignment with that of Vav shows AID 
homology in addition truncation experiments of the region show increased GEF activity towards 
RhoA (data not shown). Therefore the targeting of the DH domain strategy was employed once 
again.  
 
The Protein Data Bank was mined for novel computationally engineered structures 
containing helices that align well with the inhibitory helix. Computationally designed proteins are 
typically very stable, thus can support a large number of modification without affecting their 
stability, and should have minimal off target interactions in vivo. Initial work was with Zdark, but 
the generated inhibitors were nonspecific (data not shown). PDB ID: 2LN3 was chosen as the 
scaffold. 2LN3 is a de novo designed protein with ideal secondary structures displaying high 
thermal stability. Residues making contact with the active sight were allowed to mutate with 
position 43 set to tyr. Constraints were then set for Tyr43 on 2ln3 and Arg564 on GEF-H1 to 
maintain hydrogen bonding. The following computational protocol was utilized: docking of the 
two structures, sampling of different rotamers and amino acids for the allowed positions, followed 
by minimal backbone perturbation. Twenty thousand models were built, and the top 2,000 by ddG 
were used to generate a sequence profile from which a library was designed with SwiftLib along 
with manual inspection.   
 
VAV Library Selection: 
The Vav library generated was screened via yeast display.11) Constructs were expressed 
onto the surface of yeast as a fusion with the Aga2p protein. Display was measured by fluorescence 
labeling of a c-Myc epitope tag, while binding was measured with a biotinylated Vav2 DH/PH 
domain labeled with a streptavidin conjugated fluorophore. Cells were selected by fluorescence 
activated cell sorting (FACS). Four rounds of selection were undergone with the first three running 
the Vav2 DH/PH domain at 2uM. The last round of selection required three independent sortings. 
The first being ran against the Vav2 DH/PH domain at 300 nM, the second with the GEF-H1 
DH/PH domain at 300 nM, and lastly with 300 nm of the Vav2 DH/PH domain and 3uM of 
unlabeled GEF-H1 DH/PH domain. Selection was for constructs which showed binding towards 
Vav2, but not GEF-H1. Therefore, endowing some specificity towards Vav in addition to selecting 
against unfolded and nonselective binders.   
The above resulted in the first inhibitor termed, VI1. From there a second library was 
generated with the initial sequence being from VI1 allowing further mutations at positions 48, 52, 
53, 55, and 56. Two binders resulted from the library, VI120 and VI130.  
 
 
 
VAV inhibitor and VAV DHPH physical characterization: 
A 4xHis tag was introduced into the Vav2 
DH/PH domain. Vav2 was expressed in E coli cells 
induced with IPTG for 36 hours at 18 C Purification 
was with a Ni2+ column. SDS-PAGE gel 
electrophoresis shows the presence of Vav2 at the 
expected molecular weight of ~45 kDa. The two 
above bands could be nonspecific binding of 
proteins from the cell lysate to the Ni2+ resin.   
 
VI120 and VI130 were tagged with 
Glutathione S-transferase (GST) and purified 
with a glutathione-imobilized (GSH) column. 
The inhibitors expressed well, the SDS_PAGE 
gel shows the inhibitors present at ~20 kda. 
and had high purity.  
 
VAV inhibitor evaluation of GEF inhibition:  
A GEF activity assay was used to test GEF inhibition by inhibitors as well as GEF activity 
for the purified Vav2 DH/PH domain. Within the assay, GDP fused to the fluorescent dye BODIPY 
is bound to a known VAV GTPase target, Rac1. Upon release of GDP-BODIPY fluorescence 
output is increased which was measured with a fluorometer therefore indicating the release of 
GDP, and by extension GEF activity. To test the activity of the purified Vav2 DH/PH domain, 
different concentrations, 10uM and 5 uM, of the GEF was added to their respective GDP bound 
rac1 solutions each at the 27 min mark (Figure 7). Fluorescence increased promptly showing that 
the purified Vav2 maintained GEF activity. More so the higher concentration, 10 uM Vav2 showed 
a more robust response as compared to the 5 uM Vav2.  
 
To test the ability of the inhibitors to block Vav2-Rac1 interaction in vitro three separate 
GDP-BODIPY bound Rac1 solutions were prepared. Each received either Vav2, Vav2 and VI120, 
or Vav2 and VI130 (Figure 8). Note the difference in increase of fluorescence. Vav2 serving as 
the control has higher GEF activity as compared to the inhibitors. While VI120 and VI130 show a 
significant decrease in GEF activity at an equivalent level to each other.  
 VAV inhibitor evaluation of binding affinity: 
Binding affinity of the purified proteins 
was tested by surface plasmon resonance (SPR). 
Rac1, a known low nanomolar12) affinity binder 
for Vav, was tested as a positive control. 
However binding could not be determined at  1 
uM, 0.1 uM, and 0.01 uM due to the noise present 
in the data. Binding was detected at 100 uM, 
indicating that some portion of the purified Vav2 
DH/PH domain on the gold film was unfolded 
under the experimental conditions.   
 Utilizing the same Vav2 sample from the above experiment, VI120 was analyzed, with a 
stock concentration of 560 uM. A response was detected for the stock concentration in addition to 
both a 4x and 8x dilution. This indicates binding, but because of the noise within the system it is 
difficult to determine a dissociation. However, at our current detection levels (>10uM), VI120 
appears to bind to Vav2 similar to Rac1.  
 Analysis 
Modeling of VI120 and VI130 interaction 
 Both VI120 and VI130 were computationally modeled utilizing Rosetta to determine if 
binding affinity and specificity could be increased via the addition of further mutations. Here I will 
describe the work done with VI120. The following computational protocol was applied: The VI120 
sequence was threaded onto the Zdark backbone, thereafter docking around the DH domain with 
hydrogen bond constraints on Zdark tyr49 and Vav arg332 was undergone. This was followed by 
packing of side chains and aggressive backbone movement for several rounds. Manual inspection 
of top ddG structures, with special attention to packing of the large hydrophobics introduced in the 
second library, determined the best model for the binding of VI120 on Vav. Modeling showed that 
at position 27 the alanine present did not pack well against the DH domain. That position was 
allowed to mutate within subsequent Rosetta computational runs, it was determined that the 
introduction of an isoleucine would best fit the cavity.  
In Silico Binding specificity 
To gauge the specificity of the designed Vav inhibitors, Vav homologues with known 
structures were found with the HMMER web server. 11 such GEFs were found. To test their 
potential to interact with Vav in silico, VI120 was docked against each structure’s DH domain. 
1000 models were generated for each, which were then scored for ddG. From this data (Figure 10), 
it is clear that VI120 has preference towards Vav. As a baseline, because the inhibitor were selected 
against GEF-H1, docking runs were also undergone with the computationally predicted GEF-H1 
structure, and again preference is for Vav. A similar run was undergone with Rac1 in lieu of the 
inhibitors. There was a strong preference for Rac1 over the inhibitors as expected. To further our 
specificity analysis we looked at the relative abundance of GEFs within the breast cancer cell line, 
MDA-MB-231, where these inhibitors will be used biologically. The most prevalent GEFs of close 
homology were PDZRhoGEF, LARG, p115, and GEF-H1. Likewise VI130 in addition to VI120 
was docked against these most likely binders, and showed preference for Vav. Nevertheless our 
computational analysis indicates that both VI120 and VI130 may have significant binding toward 
PDZRhoGEF, LARG and p115. Therefore additional modelling and screening may be necessary 
to ensure absolute specificity, if such interactions are confirmed experimentally.    
 
Future Directions: 
GEF-H1 
The designed library will need to be screened experimentally, employing the same 
procedure as Vav. Once binders have been found and characterized different light-dependent 
dimers such as LOV2/Zdark11 and CRY2/CIB113, will be fused to the engineered inhibitors such 
that dimer formation will occlude the GEF-H1 binding site. Upon light irradiation, the dimer will 
dissociate, allowing the inhibitors to bind to GEF-H1 and block GTPases interaction. Dimers will 
be fused at different site and with linkers of variable length to find constructs with optimal caging 
dynamics and inhibitory properties. 
Vav2 
Pull down assays for VI120 and VI130 will be undergone to determine if there are any 
unintended binders, with special focus on identifying the presence of PDZRhoGEF, LARG, and 
p115. In addition the GEF activity assay will be performed once again with the addition of both 
LOV light and dark state mutants. Where we expect the light state mutants to not interfere with 
GEF activity inhibition, while the dark state mutant should occlude inhibition because of dimer 
formation. From there the inhibitors will be expressed in the breast cancer cell line cell line, MDA-
MB-231, to study the subcellular dynamics of Vav2.  
Conclusion 
The approach described in this thesis will allow the study of endogenous GEF-H1 and 
Vav2 with precise spatial and temporal control of activity. Other inhibition methods such as gene 
knockdown or RNAi do not provide such level of control and may lead to developmental and 
signaling artifacts in cells, which may confound biological findings. Furthermore, the inhibition 
can be applied reversibly. The approach described here is general and can be applied to develop 
inhibitors for the other 67 members of the Dbl family of GEFs. All these GEFs use a DH domain 
to activate GTPases, and in theory specific and potent inhibitors could be engineered against them 
in the future. With the exception of one small molecule developed against LARG GEF, no 
inhibitors exist for GEFs. Given that GEFs have been found to be overexpressed in cancers2) , 
these molecules could be used to study the role of GEFs in driving metastasis or as potential 
therapeutics.  
Methods 
Proteins were designed with the Rosetta macromolecular modeling software. Library 
selection for binders was done with yeast display with binding dynamics characterized by surface 
plasmon resonance. Proteins were expressed in E. Coli and underwent purification either by a Ni 
column or a glutathione column.  
Sample Rosetta Scripts 
script used to generate models for 2ln3 binding to gefh1 with constraints 
on h-bond with tyr43A and arg564B nstruct 10 with 2000 runs 
<ROSETTASCRIPTS> 
<SCOREFXNS> 
</SCOREFXNS> 
<TASKOPERATIONS> 
 <InitializeFromCommandline name="ifcm"/> 
 <ReadResfile name = "rrf" filename="clean_2ln3_gefh1.resfile"/> 
 <RestrictToRepacking name="r2p"/> 
</TASKOPERATIONS> 
<FILTERS> 
 <Sasa name="sasa" confidence="0"/> change confidence to 1 if you 
want low-sasa structures ot be supressed 
 <Ddg name="ddg" confidence="0"/> 
</FILTERS> 
<RESIDUE_SELECTORS> 
    <Index name="tyr43" resnums="43A" /> 
    <Index name="arg564" resnums="564B" /> 
</RESIDUE_SELECTORS> 
<MOVERS> 
 <AddConstraints name="add_csts" > 
                <HydrogenBondConstraintGenerator name="gen_my_csts" 
                residue_selector1="tyr43" 
                residue_selector2="arg564" 
                atoms1="OH" 
                atoms2="NH1"  
                atom_pair_func="FLAT_HARMONIC 2.6 0.1 0.5" /> 
        </AddConstraints> 
        <RemoveConstraints name="rm_csts" 
constraint_generators="gen_my_csts" /> 
 <Backrub name="bckrub"/> 
 <PackRotamersMover name="packer" task_operations="ifcm,rrf"/> 
 <Docking name="dock1" fullatom="1" local_refine="1"/> make 
fullatom=0 to do low-resolution only docking. Change local_refine=1 to do 
only high-resoltuion docking 
 <ParsedProtocol name="pack_dock" > 
  <Add mover_name="dock1"/> 
  <Add mover_name="packer"/> 
  <Add mover_name="bckrub"/> 
 </ParsedProtocol> 
 <LoopOver name="loop" mover_name="pack_dock" iterations="10"/> 
</MOVERS> 
<APPLY_TO_POSE> 
</APPLY_TO_POSE> 
<PROTOCOLS> 
 <Add mover="add_csts" /> 
 <Add mover_name="loop"/> 
 <Add mover="rm_csts" /> 
 <Add filter_name="sasa"/> 
 <Add filter_name="ddg"/> 
</PROTOCOLS> 
</ROSETTASCRIPTS> 
 
Script used to model VI120 and VI130 inhibitors with restriction of 
backbone movement of DHPH domain  
<ROSETTASCRIPTS> 
<SCOREFXNS> 
</SCOREFXNS> 
<TASKOPERATIONS> 
 <InitializeFromCommandline name="ifcm"/> 
 <ReadResfile name = "rrf" 
filename="/nas02/home/l/y/lyayuga/Zdrklibrary/VAV_Zdrk/resfile/VAV_Zdrk_VI
20n30_DHPH.resfile"/> 
 <RestrictToRepacking name="r2p"/> 
</TASKOPERATIONS> 
<FILTERS> 
 <Sasa name="sasa" confidence="0"/> change confidence to 1 if you 
want low-sasa structures ot be supressed 
 <Ddg name="ddg" confidence="1" threshold="0"/> 
 <ShapeComplementarity name="sc" confidence="0"/> 
 <BuriedUnsatHbonds name="unsatH" confidence="0"/> 
</FILTERS> 
<RESIDUE_SELECTORS> 
    <Index name="tyr49" resnums="49C" /> 
    <Index name="arg332" resnums="332B" /> 
</RESIDUE_SELECTORS> 
<MOVERS> 
 <FastRelax name="flax" repeats="5" task_operations="r2p,rrf" 
batch="false" ramp_down_constraints="false" cartesian="false" 
bondangle="false" bondlength="false" min_type="dfpmin_armijo_nonmonotone"> 
  <MoveMap> 
         <Chain number="2" chi="1" bb="0"/> restrict backbone 
movement for DHPH 
     </MoveMap> 
 </FastRelax> 
 <DockingProtocol name="dock2" low_res_protocol_only="0" 
docking_local_refine="0" dock_min="1" ignore_default_docking_task="0" 
task_operations="r2p,rrf" partners="B_C"/> 
 <AddConstraints name="add_csts" > 
                <HydrogenBondConstraintGenerator name="gen_my_csts" 
                residue_selector1="tyr49" 
                residue_selector2="arg332" 
                atoms1="OH" 
                atoms2="NH1"  
                atom_pair_func="FLAT_HARMONIC 2.6 0.1 0.5" /> 
        </AddConstraints> 
        <RemoveConstraints name="rm_csts" 
constraint_generators="gen_my_csts" /> 
 <Backrub name="bckrub"/> 
 <PackRotamersMover name="packer" task_operations="ifcm,rrf"/> 
 <Docking name="dock1" fullatom="1" local_refine="1"/> make 
fullatom=0 to do low-resolution only docking. Change local_refine=1 to do 
only high-resoltuion docking 
 <ParsedProtocol name="pack_dock" > 
  <Add mover_name="dock2"/> 
  <Add mover_name="packer"/> 
  <Add mover_name="bckrub"/> 
  <Add mover="flax" /> 
 </ParsedProtocol> 
 <LoopOver name="loop" mover_name="pack_dock" iterations="5"/> 
 <SwitchResidueTypeSetMover name="fa_switch" set="fa_standard"/> 
</MOVERS> 
<APPLY_TO_POSE> 
</APPLY_TO_POSE> 
<PROTOCOLS> 
 <Add mover="add_csts" /> 
 <Add mover_name="loop"/> 
 <Add mover="rm_csts" /> 
 <Add filter_name="sasa"/> 
 <Add filter_name="sc"/> 
 <Add filter_name="unsatH"/> 
 <Add filter_name="ddg"/> 
</PROTOCOLS> 
</ROSETTASCRIPTS> 
 
Sample Purification Protocol 
Batch Protein purification 
 
1. Resuspend in 15mL GST wash buffer (w/ 1mM DTT)+ 2.5uL Lysozyme + protein inhibitor 
pallet 
 
2. Sonicate 15s on/15s off for 3 mins on ice. (Reserve 20uL as Lysate fraction) 
 
3. Transfer to 30 mL centrifuge tube 
 
4. Spin 16,000 RPM 4C 35 minutes (Reserve 20uL supernatant as Cleared Lysate fraction) 
 
Equilibrate resin 
 
5. Add 1 mL of GST-agarose slurry to 15 mL falcon tube 
 
6. Centrifuge for 2 min at 700 x g 
 
7. Decant supernatant 
 
8. Resuspend resin in 3 mL wash buffer 
 
9. Centrifuge for 2 min at 700 x g 
 
10. Decant supernatant 
 
11. Resuspend reins in 3 mL wash buffer 
 
12. Centrifuge for 2 min at 700 x g 
 
13. Decant supernatant (Do this immediately before the following step so that the resin does not 
out) 
 
Incubation 
 
13. Add clarified lysate to washed resin 
 
14. resuspend resin. 
 
15. rotate end over end for 1 h (reserve 20 uL) 
 
Column 
 
16. Add entire sample to column (collect 20 uL of flow through) 
 
17. Wash with 5 mL of wash buffer (collect 20 uL of wash) 
 
18. Add 1 mL Elution buffer to top of column 
 
19. Allow to drain into 1.5 mL microfuge tube (Elution fraction 1) 
 
20. Add 1 mL Elution buffer to top of column 
 
21. Allow to drain into 1.5 mL microfuge tube (Elution fraction 2) 
 
22. Add 1 mL Elution buffer to top of column 
 
23. Allow to drain into 1.5 mL microfuge tube (Elution fraction 3) 
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